A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

Phase 3

PF-08634404 with PembrolizumabA Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor:

Pfizer

Code:

NCT07222566

Conditions

Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung (NSCLC)

Metastatic Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PF-08634404

Pembrolizumab

Chemotherapy Regimen 1

Chemotherapy Regimen 2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-01. This information was provided to ClinicalTrials.gov by Pfizer on 2026-01-23.